Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2021-05, Vol.39 (15), p.1609-1618
Hauptverfasser:	Fowler, Nathan H, Samaniego, Felipe, Jurczak, Wojciech, Ghosh, Nilanjan, Derenzini, Enrico, Reeves, James A, Knopińska-Posłuszny, Wanda, Cheah, Chan Y, Phillips, Tycel, Lech-Maranda, Ewa, Cheson, Bruce D, Caimi, Paolo F, Grosicki, Sebastian, Leslie, Lori A, Chavez, Julio C, Fonseca, Gustavo, Babu, Sunil, Hodson, Daniel J, Shao, Spencer H, Burke, John M, Sharman, Jeff P, Law, Jennie Y, Pagel, John M, Miskin, Hari P, Sportelli, Peter, O'Connor, Owen A, Weiss, Michael S, Zinzani, Pier Luigi
Format:	Artikel
Sprache:	eng
Schlagworte:	Female Heterocyclic Compounds, 4 or More Rings - pharmacology Heterocyclic Compounds, 4 or More Rings - therapeutic use Humans Lymphoma - drug therapy Male Neoplasm Recurrence, Local - drug therapy RAPID COMMUNICATIONS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!